X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (48727) 48727
Book Review (8568) 8568
Publication (5345) 5345
Newsletter (2515) 2515
Newspaper Article (816) 816
Book Chapter (466) 466
Book / eBook (226) 226
Conference Proceeding (136) 136
Magazine Article (89) 89
Dissertation (27) 27
Trade Publication Article (18) 18
Transcript (14) 14
Data Set (11) 11
Web Resource (10) 10
Reference (9) 9
Report (5) 5
Paper (1) 1
Presentation (1) 1
Streaming Video (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (43969) 43969
humans (28051) 28051
animals (25218) 25218
female (14962) 14962
mice (13168) 13168
immunology (12736) 12736
antibodies (11977) 11977
male (11501) 11501
viruses (9707) 9707
viral antibodies (9433) 9433
virology (9415) 9415
health aspects (9252) 9252
infections (7609) 7609
vaccines (7254) 7254
proteins (7213) 7213
research (7201) 7201
infection (7034) 7034
infectious diseases (6783) 6783
adult (6499) 6499
analysis (6284) 6284
microbiology (5963) 5963
medicine, research & experimental (5855) 5855
middle aged (5588) 5588
vaccination (5476) 5476
research article (5425) 5425
virus diseases (5261) 5261
medicine (4937) 4937
viral infections (4709) 4709
mice, inbred balb c (4633) 4633
antibodies, viral - blood (4549) 4549
immunization (4545) 4545
antigens (4494) 4494
multidisciplinary sciences (4342) 4342
gene expression (4063) 4063
cancer (3912) 3912
immune response (3841) 3841
care and treatment (3794) 3794
science (3780) 3780
pharmacology & pharmacy (3718) 3718
expression (3709) 3709
biotechnology & applied microbiology (3513) 3513
viral vaccines - immunology (3490) 3490
medical research (3436) 3436
article (3384) 3384
viral load (3366) 3366
in-vivo (3361) 3361
t cells (3320) 3320
cell line (3306) 3306
hiv (3273) 3273
treatment outcome (3144) 3144
genetic aspects (3142) 3142
vaccine (3108) 3108
disease models, animal (3106) 3106
influenza (3084) 3084
antiviral agents - therapeutic use (3062) 3062
immunity (3061) 3061
abridged index medicus (2994) 2994
biology (2973) 2973
dna (2946) 2946
mice, inbred c57bl (2909) 2909
lymphocytes (2903) 2903
therapy (2896) 2896
interferon (2883) 2883
aged (2861) 2861
disease (2837) 2837
gene therapy (2732) 2732
veterinary sciences (2720) 2720
antiviral agents (2710) 2710
biology and life sciences (2710) 2710
cells (2686) 2686
cytokines (2678) 2678
biochemistry & molecular biology (2659) 2659
studies (2657) 2657
genetic vectors (2647) 2647
viral vaccines - administration & dosage (2637) 2637
enzyme-linked immunosorbent assay (2636) 2636
physiological aspects (2623) 2623
cell biology (2607) 2607
hepatitis (2578) 2578
medicine and health sciences (2504) 2504
oncology (2472) 2472
dendritic cells (2439) 2439
immunogenicity (2387) 2387
antibodies, viral - immunology (2386) 2386
molecular sequence data (2384) 2384
allergy and immunology (2376) 2376
immunotherapy (2358) 2358
rna (2353) 2353
virus (2334) 2334
immune system (2328) 2328
adolescent (2259) 2259
immunoglobulins (2243) 2243
replication (2236) 2236
drug therapy (2235) 2235
genes (2208) 2208
gastroenterology & hepatology (2201) 2201
human immunodeficiency virus--hiv (2177) 2177
inflammation (2158) 2158
risk factors (2158) 2158
prevention (2141) 2141
more...
Library Location Library Location
Library Location Library Location
X
Sort by Item Count (A-Z)
Filter by Count
Gerstein Science - Stacks (172) 172
Collection Dvlpm't (Acquisitions) - Closed Orders (16) 16
Collection Dvlpm't (Acquisitions) - Vendor file (11) 11
UTL at Downsview - May be requested (10) 10
Online Resources - Online (8) 8
UofT at Mississauga - Stacks (8) 8
UofT at Scarborough - Stacks (7) 7
Earth Sciences (Noranda) - Stacks (4) 4
Gerstein Science - Circulation Desk (2) 2
Gerstein Science - Course Reserves (2) 2
Sunnybrook Health Sciences Centre - Sunnybrook Stacks (2) 2
Credit Valley Hospital - Stacks (1) 1
Dentistry (Harry R Abbott) - May be requested in 6-10 wks (1) 1
Gerstein Science - Missing (1) 1
Lakeridge Health Sciences - Oshawa (1) 1
Law (Bora Laskin) - Stacks (1) 1
New College (Ivey) - Stacks (1) 1
Robarts - Stacks (1) 1
St. Michael's College (John M. Kelly) - 2nd Floor (1) 1
UofT at Scarborough - Withdrawn (1) 1
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (52207) 52207
Chinese (97) 97
Russian (87) 87
French (86) 86
Japanese (61) 61
German (55) 55
Spanish (45) 45
Polish (14) 14
Hungarian (11) 11
Italian (7) 7
Korean (7) 7
Portuguese (5) 5
Dutch (4) 4
Norwegian (4) 4
Croatian (3) 3
Czech (3) 3
Turkish (3) 3
Bulgarian (2) 2
Serbian (2) 2
Slovak (2) 2
Swedish (2) 2
Danish (1) 1
Hebrew (1) 1
Ukrainian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Nature, ISSN 0028-0836, 07/2007, Volume 448, Issue 7149, pp. 39 - 43
A major impediment in the treatment of neurological diseases is the presence of the blood - brain barrier, which precludes the entry of therapeutic molecules... 
IN-VIVO DELIVERY | VIRUS | TRANSPORTERS | MULTIDISCIPLINARY SCIENCES | INTRACELLULAR DELIVERY | CELL-PENETRATING PEPTIDES | GENE-THERAPY | RECEPTORS | MODIFIED SIRNAS | BRAIN | INHIBITS TUMOR-GROWTH | RNA, Small Interfering - genetics | Superoxide Dismutase - genetics | Encephalitis Virus, Japanese | Humans | Glycoproteins - metabolism | Brain - virology | Molecular Sequence Data | Green Fluorescent Proteins - genetics | Viral Proteins - metabolism | Drug Delivery Systems | Brain - metabolism | Lentivirus - genetics | Viral Proteins - administration & dosage | Neurons - metabolism | Glycoproteins - genetics | Recombinant Proteins - metabolism | Amino Acid Sequence | Cell Line | Neurons - virology | Rabies virus - physiology | Receptors, Nicotinic - metabolism | Mice, Inbred C57BL | Oligopeptides - genetics | Gene Silencing | Viral Proteins - genetics | Recombinant Proteins - genetics | Mice, SCID | Genetic Vectors - genetics | Glycoproteins - administration & dosage | Recombinant Proteins - administration & dosage | Rabies virus - genetics | Animals | Encephalitis, Japanese - prevention & control | Mice, Inbred NOD | Mice | Mice, Inbred BALB C | HeLa Cells | Liposomes | Superoxide Dismutase-1 | RNA, Small Interfering - administration & dosage | Blood-Brain Barrier | RNA, Small Interfering - metabolism | Brain cells | Research | Brain | Nervous system | Amino acids | Peptides | Neurological disorders | Blood | Blood-brain barrier | Ribonucleic acids | Cytokines | Genes | Central nervous system | Index Medicus
Journal Article
Journal Article
Vaccine, ISSN 0264-410X, 2017, Volume 35, Issue 11, pp. 1509 - 1516
Highlights • GTL001 is a bivalent CyaA-HPV16 E7/CyaA-HPV18 E7 therapeutic vaccine. • GTL001-induced effector and prophylactic memory T-cell responses eradicate... 
Allergy and Immunology | Tumour-associated antigen | Tumour model | Human papillomavirus | Therapeutic vaccine | Cervical cancer | Memory T-cell response | MEDICINE, RESEARCH & EXPERIMENTAL | METAANALYSIS | DENDRITIC CELLS | ADENYLATE-CYCLASE TOXIN | IMMUNOLOGY | CUTTING EDGE | IMIQUIMOD | IMMUNIZATION | IMMUNE-SYSTEM | E7 ONCOPROTEIN | BORDETELLA-PERTUSSIS | ESTABLISHED TUMORS | Oncogene Proteins, Viral - administration & dosage | Adjuvants, Immunologic - administration & dosage | Neoplasm Proteins - administration & dosage | Ovalbumin - immunology | Papillomavirus Vaccines - genetics | Neoplasm Proteins - immunology | Papillomavirus E7 Proteins - immunology | Drug Carriers - administration & dosage | Vaccines, Synthetic - immunology | Adenylate Cyclase Toxin - genetics | Papillomavirus E7 Proteins - genetics | Antigens, Neoplasm - administration & dosage | Cancer Vaccines - genetics | Melanoma - prevention & control | DNA-Binding Proteins - administration & dosage | Female | Oncogene Proteins, Viral - genetics | Neoplasm Proteins - genetics | Papillomavirus Vaccines - administration & dosage | Disease Models, Animal | Injections, Intradermal | Ovalbumin - genetics | Antigens, Neoplasm - genetics | Papillomavirus Infections - complications | DNA-Binding Proteins - immunology | Ovarian Neoplasms - prevention & control | Antigens, Neoplasm - immunology | Cancer Vaccines - administration & dosage | Mice, Inbred C57BL | Vaccines, Synthetic - genetics | Uterine Cervical Neoplasms - prevention & control | Treatment Outcome | Adenylate Cyclase Toxin - administration & dosage | DNA-Binding Proteins - genetics | Cancer Vaccines - immunology | Animals | Ovalbumin - administration & dosage | Papillomavirus E7 Proteins - administration & dosage | Immunologic Memory | Papillomavirus Vaccines - immunology | T-Lymphocytes - immunology | Oncogene Proteins, Viral - immunology | Vaccines, Synthetic - administration & dosage | Antigens | Care and treatment | Vaccines | T cells | Health aspects | Papillomavirus infections | Tumors | Cancer | Peptides | Stock options | Dendritic cells | Cloning | Melanoma | Amino acids | Employees | T cell receptors | Infections | Experiments | Proteins | Cellular biology | Index Medicus
Journal Article
Vaccine, ISSN 0264-410X, 2012, Volume 31, Issue 3, pp. 524 - 532
Highlights ► This Phase 1 trial evaluated the safety and immunogenicity of an RSV (F) nanoparticle vaccine. ► The vaccine was well-tolerated and no related... 
Allergy and Immunology | Respiratory syncytial virus (RSV) | Palivizumab | Fusion protein (F protein) | Competitive ELISA | SF9 insect cell | Microneutralization | Aluminum phosphate | Anti-F IgG | Nanoparticle vaccine | UNITED-STATES | MEDICINE, RESEARCH & EXPERIMENTAL | NEUTRALIZING ANTIBODIES | IMMUNE GLOBULIN | COTTON RATS | INFLUENZA | RISK | IMMUNOLOGY | F-GLYCOPROTEIN | INFANTS | INFECTION | YOUNG-CHILDREN | Recombinant Fusion Proteins - immunology | Single-Blind Method | Biotechnology | Respiratory Syncytial Virus Vaccines - immunology | Adjuvants, Immunologic - administration & dosage | Aluminum Compounds - adverse effects | Phosphates - administration & dosage | Recombinant Fusion Proteins - adverse effects | Humans | Middle Aged | Male | Nanoparticles - adverse effects | Vaccines, Synthetic - immunology | Antibodies, Viral - blood | Adjuvants, Immunologic - adverse effects | Young Adult | Respiratory Syncytial Virus Vaccines - adverse effects | Sf9 Cells | Technology, Pharmaceutical | Vaccines, Virosome - immunology | Vaccines, Synthetic - adverse effects | Placebos - adverse effects | Adult | Female | Placebos - administration & dosage | Recombinant Fusion Proteins - administration & dosage | Vaccines, Virosome - administration & dosage | Vaccines, Synthetic - genetics | Vaccines, Virosome - genetics | Animals | Aluminum Compounds - administration & dosage | Phosphates - adverse effects | Vaccines, Virosome - adverse effects | Respiratory Syncytial Virus Vaccines - administration & dosage | Adolescent | Recombinant Fusion Proteins - genetics | Nanoparticles - administration & dosage | Vaccines, Synthetic - administration & dosage | Respiratory Syncytial Virus Vaccines - genetics | Antibodies, Neutralizing - blood | Virus diseases | Phosphates | Vaccines | Immunoglobulin G | Enzyme-linked immunosorbent assay | Proteins | Nanoparticles | Infections | Index Medicus
Journal Article
Blood, ISSN 0006-4971, 2009, Volume 113, Issue 25, pp. 6304 - 6314
Interleukin 7 (IL- 7) is a common gamma chain receptor cytokine implicated in thymopoiesis and in peripheral expansion and survival of T lymphocytes. The... 
INDIVIDUALS | HOMEOSTASIS | CD127 EXPRESSION | DECREASED CD127 | DISEASE | ANTIRETROVIRAL THERAPY | HUMAN-IMMUNODEFICIENCY-VIRUS | HEMATOLOGY | IMMATURE/TRANSITIONAL B-CELLS | INTERLEUKIN-7 RECEPTOR | GAMMA-CHAIN | HIV-1 | Recombinant Proteins - therapeutic use | T-Lymphocyte Subsets - immunology | CD8-Positive T-Lymphocytes - cytology | T-Lymphocyte Subsets - cytology | Humans | Middle Aged | Interleukin-7 - pharmacology | Male | Recombinant Proteins - adverse effects | Immunologic Memory - drug effects | Interleukin-7 Receptor alpha Subunit - biosynthesis | Viral Load | Interleukin-7 - administration & dosage | T-Lymphocytes, Regulatory - immunology | CD4-Positive T-Lymphocytes - immunology | HIV Infections - immunology | T-Lymphocyte Subsets - drug effects | T-Lymphocytes, Regulatory - cytology | CD8-Positive T-Lymphocytes - metabolism | Adult | Female | Interleukin-7 Receptor alpha Subunit - genetics | Interleukin-7 - blood | Chemical and Drug Induced Liver Injury - etiology | CD4-Positive T-Lymphocytes - cytology | CD4-Positive T-Lymphocytes - metabolism | Recombinant Proteins - pharmacology | Down-Regulation - drug effects | Recombinant Proteins - administration & dosage | Recombinant Proteins - blood | Maximum Tolerated Dose | T-Lymphocytes, Regulatory - drug effects | CD8-Positive T-Lymphocytes - drug effects | Interleukin-7 - therapeutic use | Lymphocyte Count | HIV Infections - drug therapy | CD8-Positive T-Lymphocytes - immunology | Cell Cycle - drug effects | Interleukin-7 - adverse effects | CD4-Positive T-Lymphocytes - drug effects | Index Medicus | Abridged Index Medicus | Clinical Trials and Observations
Journal Article
Hepatology, ISSN 0270-9139, 12/2013, Volume 58, Issue 6, pp. 1918 - 1929
Journal Article
The Journal of Immunology, ISSN 0022-1767, 09/2008, Volume 181, Issue 6, pp. 4168 - 4176
Journal Article
Vaccine, ISSN 0264-410X, 12/2017, Volume 35, Issue 50, pp. 7026 - 7032
A highly effective antigen construct for presenting conserved antigen domains is essential to the development of a universal influenza vaccine. We have... 
Conserved domains | Vaccine | Dual-domain | Nanoparticle | Influenza | ANTIBODIES | MEDICINE, RESEARCH & EXPERIMENTAL | FUSION | PROTECTION | SUBTYPES | EXTRACELLULAR DOMAIN | IMMUNOLOGY | PEPTIDE | DEPENDENT CELLULAR CYTOTOXICITY | M2 PROTEIN | A VIRUS HEMAGGLUTININ | PROSPECTS | Recombinant Fusion Proteins - immunology | Influenza Vaccines - administration & dosage | Viral Matrix Proteins - genetics | Vaccines, Synthetic - genetics | Bacterial Proteins - genetics | Drug Carriers - administration & dosage | Antigens, Viral - genetics | Hemagglutinin Glycoproteins, Influenza Virus - immunology | Vaccines, Synthetic - immunology | DNA-Binding Proteins - genetics | Antibodies, Viral - blood | Bacterial Proteins - administration & dosage | Hemagglutinin Glycoproteins, Influenza Virus - genetics | Antigens, Viral - immunology | Animals | Influenza Vaccines - immunology | Influenza Vaccines - genetics | DNA-Binding Proteins - administration & dosage | Recombinant Fusion Proteins - genetics | Mice, Inbred BALB C | Nanoparticles - administration & dosage | Viral Matrix Proteins - immunology | Vaccines, Synthetic - administration & dosage | Influenza vaccines | Proteins | Antigens | Bacteria | Protein binding | Epidemics | Immunoglobulins | Pandemics | Archaea | Cytotoxicity | Viruses | Amino acids | Vaccines | Virology | Nanoparticles | Survival analysis | Phylogenetics | Fusion protein | Deoxyribonucleic acid--DNA | Index Medicus | nanoparticle | vaccine | dual-domain | conserved domains
Journal Article
Lancet Infectious Diseases, The, ISSN 1473-3099, 2013, Volume 13, Issue 5, pp. 401 - 408
Summary Background Protease inhibitors have improved treatment of infection with hepatitis C virus (HCV), but dosing, a low barrier to resistance, drug... 
Infectious Disease | PSI-7977 | INFECTIOUS DISEASES | PLUS RIBAVIRIN | VIRUS-INFECTION | TELAPREVIR | BOCEPREVIR | INHIBITORS | Recombinant Proteins - therapeutic use | Uridine Monophosphate - administration & dosage | Nausea - chemically induced | Humans | Middle Aged | Hepatitis C, Chronic - virology | Hepacivirus - pathogenicity | Male | Secondary Prevention | Polyethylene Glycols - therapeutic use | Young Adult | Time Factors | Ribavirin - administration & dosage | Adult | Female | Headache - chemically induced | Uridine Monophosphate - therapeutic use | Double-Blind Method | Antiviral Agents - therapeutic use | Ribavirin - therapeutic use | Interferon-alpha - therapeutic use | RNA, Viral - analysis | Genotype | Treatment Outcome | Hepatitis C, Chronic - drug therapy | Antiviral Agents - administration & dosage | Polyethylene Glycols - administration & dosage | Recombinant Proteins - administration & dosage | Interferon-alpha - administration & dosage | Drug Therapy, Combination - methods | Antiviral Agents - adverse effects | Uridine Monophosphate - analogs & derivatives | Adolescent | Liver Cirrhosis - pathology | Aged | Hepacivirus - classification | Sofosbuvir | Care and treatment | Protease inhibitors | Proteases | Gastrointestinal diseases | Clinical trials | Product development | Genetic aspects | Interferon | Hepatitis C | Health aspects | Liver cirrhosis | Viral antigens | Index Medicus
Journal Article
The Journal of Infectious Diseases, ISSN 0022-1899, 12/2017, Volume 216, Issue 11, pp. 1362 - 1370
Journal Article